Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43772
UPID:
MCAT_HUMAN
Alternative names:
Carnitine/acylcarnitine translocase; Solute carrier family 25 member 20
Alternative UPACC:
O43772; B2R7F4; Q9UIQ2
Background:
The Mitochondrial carnitine/acylcarnitine carrier protein, also known as Carnitine/acylcarnitine translocase and Solute carrier family 25 member 20, plays a crucial role in the mitochondrial oxidation pathway. It facilitates the exchange of acylcarnitines with free carnitine across the mitochondrial inner membrane, essential for fatty acid beta-oxidation.
Therapeutic significance:
Carnitine-acylcarnitine translocase deficiency, a rare but severe metabolic disorder, is directly linked to mutations in the gene encoding this protein. Understanding its function could lead to novel therapeutic strategies for managing this life-threatening condition.